BRD2 and cancer: There were no statistically significant differences in OS (20 months for SURG and 24 months for NAT, p = 0.7708) or cancer-related survival (21 months for SURG and 18 months for NAT, p = 0.0827) between the SURG and the NAT group (Figure 1a,b).